Form 8.5 (EPT/RI)-Advanced Medical Solutions Group plc

Investec Bank, acting as adviser and joint broker to Advanced Medical Solutions Group, disclosed client-serving trades on 23 September 2026: purchases of 482,525 ordinary shares and sales of 151,582 shares, all at 282.25p per share. The Rule 8.5 Takeover Code filing reported no cash- or stock-settled derivative activity and no indemnity, option, or other dealing arrangements. The disclosure is a routine regulatory notification and does not indicate a change in the offer terms or company fundamentals.

Analysis

This is broker facilitation flow, not informed proprietary accumulation or a change in deal probability. The matched activity leaves Investec with a modest net purchase of 330,943 shares, but recognised-intermediary disclosures are designed to report client-serving market making and should not be interpreted as advisor conviction, bidder support, or a voting signal. With no derivative activity or disclosed arrangement, there is no evidence here of a developing competing-offer structure.

The relevant near-term mechanism is technical: concentrated turnover at a single price can temporarily improve liquidity around the transaction reference level and reduce execution friction for arbitrage funds. That effect is likely measured in days, not weeks; absent a formal offer document, acceptance-progress disclosure, revised terms, or a new Rule 2.7/2.4 announcement, it provides no basis to revise standalone downside or completion odds.

Contrarian risk is that market participants overread any broker dealing disclosure as a directional signal. In UK takeovers, the more valuable indicators are the spread versus cash consideration after adjusting for expected closing date, regulatory-condition developments, and irrevocable/acceptance support. A widening spread on no fundamental news would be an execution/liquidity opportunity only if position sizing can withstand a break-risk repricing to the unaffected valuation.

Key Decisions for Investors

• No directional trade based solely on this disclosure; classify as neutral market-making flow and avoid treating INVP activity as an M&A signal.
• For an existing AMS deal-arbitrage position, monitor the annualized gross spread daily versus the stated cash consideration and expected closing date; add only if spread widening is unsupported by a regulatory, financing, or acceptance-related development.
• Set alerts for a formal offer-term revision, competition authority update, acceptance threshold disclosure, or a new bidder statement over the next 1-3 months; these are the events that can change completion probability and justify repricing.
• If AMS liquidity weakens materially, reduce position size rather than infer negative information from intermediary prints; the principal risk remains gap-down break risk to standalone value, not the reported broker inventory.